NYSEAMERICAN:CVRS - Corindus Vascular Robotics Stock Price, Price Target & More

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) released its earnings results on Tuesday, May, 8th. The medical equipment provider reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.03. The medical equipment provider had revenue of $1.49 million for the quarter, compared to analysts' expectations of $3.20 million. Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%. View Corindus Vascular Robotics' Earnings History.

2 equities research analysts have issued 1 year price targets for Corindus Vascular Robotics' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Corindus Vascular Robotics' share price to reach $2.00 in the next year. View Analyst Ratings for Corindus Vascular Robotics.

Corindus Vascular Robotics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 13,031,745 shares, an increase of 7.4% from the April 30th total of 12,138,919 shares. Based on an average daily trading volume, of 1,118,686 shares, the days-to-cover ratio is currently 11.6 days. Approximately 14.8% of the company's stock are short sold.

Some companies that are related to Corindus Vascular Robotics include Consort Medical (CSRT), Ekf Diagnostics (EKF), Bioquell (BQE), Immunodiagnostic Systems (IDH), Zecotek Photonics (ZMS), Theralase Technologies (TLT), Lidco Group (LID), MedaPhor Group (MED), InspireMD (NSPR), Lucid (LCDX), Verisante Technology (VRS) and Deltex Medical Group (DEMG).

Press coverage about CVRS stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corindus Vascular Robotics earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 47.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Corindus Vascular Robotics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.30%), Migdal Insurance & Financial Holdings Ltd. (0.11%), Bronfman E.L. Rothschild L.P. (0.06%) and The Manufacturers Life Insurance Company (0.05%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.

CVRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Migdal Insurance & Financial Holdings Ltd., Bronfman E.L. Rothschild L.P. and The Manufacturers Life Insurance Company . Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP, Jeffrey Gold and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.

Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CVRS stock can currently be purchased for approximately $0.7895.

Corindus Vascular Robotics has a market capitalization of $272.68 million.

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.